CTOs on the Move

Genesys Spine

www.genesysspine.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.genesysspine.com
  • 1250, South Capital of Texas Highway
    Austin, TX USA 78746
  • Phone: 512.381.7070

Executives

Name Title Contact Details

Similar Companies

Kyowa Kirin

Kyowa Kirin Co., Ltd.

Advanced Pain Care

Advanced Pain Care is here to help your chronic and acute pain, with 11 locations across Central Texas and Amarillo. Call us and stop the pain today.

KORU Medical

The home infusion industry turns to KORU Medical Systems to help patients and medical professionals improve infusion therapy experiences and we have a passion and vision for doing just that! We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers with careful consideration to the patient experience. The company was incorporated in March 1980 and is now publicly traded on the NASDAQ Capital Market (NASDAQ: KRMD). We are located in Chester, NY (USA), just 60 miles northwest of New York City. Our primary products include the FREEDOM60® and FreedomEdge® Syringe Infusion Systems, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets.

UQUIFA

UQUIFA is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical and animal health industries globally

Dragon Pharmaceuticals

Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in China, Egypt, India and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East.